Abstract
Objective To assess the comparative efficacy and safety of approved biologic disease-modifying antirheumatic drugs (bDMARDs), biosimilars, and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) for patients with rheumatoid arthritis (RA) who had inadequate responses to methotrexate (MTX).
Results 53 eligible studies were identified and 44 studies were included in a network meta-analysis. Using Surface Under the Cumulative Ranking Curve (SUCRA), tofacitinib (10 mg bid) with MTX [Relative risk (RR) 95% confidence interval (CI) 4.65 (2.98-7.27)] and tofacitinib (10 mg bid) [RR (95%CI)1.96 (1.27-3.03)] were ranked highest among tsDMARDs for increasing remission rate at 24-26 weeks and 48-52 weeks, respectively. For bDMARDs, tocilizumab (8 mg/kg) with MTX was ranked with highest treatment effect for remission at both 24-26 and 48-52 weeks [RR (95%CI) 3.06 (2.27-4.12); RR (95%CI) 2.52 (1.94-3.28)]. For safety, baricitinib (4 mg) and tofacitinib (5 mg bid) with MTX likely showed an increased risk of HZ with statistical significance [for baricitinib, RR (95%CI) 3.52 (1.38-9.02) at 24-26 weeks, and RR (95%CI) 4.20 (1.22-14.48) at 48-52 weeks, and for tofacitinib, RR (95%CI) 5.38 (1.00-28.91) at 48-52 weeks]. No statistically significant safety concerns for serious infection, tuberculosis (TB), cancer, and cardiovascular (CV) events were identified.
Conclusions For RA patients who failed MTX, bDMARDs, biosimilars, and tsDMARDs monotherapy and combination therapy with MTX provided better treatment outcomes than MTX monotherapy with modest safety concerns within 24-52 weeks. A scarcity of longer-term effects and post-market surveillance necessitates further analyses using long-term patient-level data to improve the medication profile.
Rheumatology key messages
For RA patients who failed MTX and other conventional DMARDs, different types of DMARDs are available.
At dose- and time point-specific levels, tofacitinib (10 mg bd) showed the highest probability to be the most effective in achieving remission at 24-26 weeks.
An increased risk of herpes zoster was found for baricitinib (4 mg) and tofacitinib (5 mg bid) with MTX.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Health System Research Institute (HSRI) grant number 63-048
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was supported by Health System Research Institute (HSRI) grant number 63-048 and Health Intervention and Technology Assessment Program (HITAP) project number 63111002RM009L0. Five of the eight authors were HITAP employees during the study period. The funders have not been directly involved in any stage of developing this article or decision to publish.
Competing interests: All authors have completed the ICMJE unified disclosure form. No conflict of interest was declared.
Ethical approval: Not required
Nuttakarn.bud{at}mahidol.edu
Juthamas.pra{at}mahidol.edu
Pattara.lee{at}mahidol.edu
Spilasant{at}usaid.gov
nanchonti1012{at}gmail.com
Npongthorn{at}yahoo.com
Pekungsang{at}yahoo.com
Wanruchada.kat{at}mahidol.ac.th
Data Availability
Main data produced in the present work are contained in the manuscript. Additional data produced in the present work are available upon reasonable request to the authors.